CoChat

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis

Open access

Abstract

Rationale: Although persistent fibroblast activation is a hallmark of idiopathic pulmonary fibrosis (IPF), mechanisms regulating persistent fibroblast activation in the lungs have not been fully elucidated. Objectives: On the basis of our observation that lung fibroblasts express TBXA2R (thromboxane–prostanoid receptor) during fibrosis, we investigated the role of TBXA2R signaling in fibrotic remodeling. Methods: We identified TBXA2R expression in lungs of patients with IPF and mice and studied primary mouse and human lung fibroblasts to determine the impact of TBXA2R signaling on fibroblast activation. We used TBXA2R-deficient mice and small-molecule inhibitors to investigate TBXA2R signaling in preclinical lung fibrosis models. Measurements and Main Results: TBXA2R expression was upregulated in fibroblasts in the lungs of patients with IPF and in mouse lungs during experimental lung fibrosis. Genetic deletion of TBXA2R, but not inhibition of thromboxane synthase, protected mice from bleomycin-induced lung fibrosis, thereby suggesting that an alternative ligand activates profibrotic TBXA2R signaling. In contrast to thromboxane, F2-isoprostanes, which are nonenzymatic products of arachidonic acid induced by reactive oxygen species, were persistently elevated during fibrosis. F2-isoprostanes induced TBXA2R signaling in fibroblasts and mediated a myofibroblast activation profile due, at least in part, to potentiation of TGF-β (transforming growth factor-β) signaling. In vivo treatment with the TBXA2R antagonist ifetroban reduced profibrotic signaling in the lungs, protected mice from lung fibrosis in three preclinical models (bleomycin, Hermansky-Pudlak mice, and radiation-induced fibrosis), and markedly enhanced fibrotic resolution after bleomycin treatment. Conclusions: TBXA2R links oxidative stress to fibroblast activation during lung fibrosis. TBXA2R antagonists could have utility in treating pulmonary fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202106-1503oc

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

See all 27

Metadata

Authors
Suzuki, T., Kropski, J. A., Chen, J., Carrier, E. J., Chen, X., Sherrill, T. P., Winters, N. I., Camarata, J. E., Polosukhin, V. V., Han, W., Rathinasabapathy, A., Gutor, S., Gulleman, P., Sabusap, C., Banovich, N. E., Tanjore, H., Freeman, M. L., Tada, Y., Young, L. R., Gokey, J. J., Blackwell, T. S., & West, J. D.
Affiliations
  • University of Tsukuba (JP)
  • Vanderbilt University (US)
  • Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, and
  • Translational Genomics Research Institute (US)
  • Vanderbilt University Medical Center (US)
  • International University of Health and Welfare (JP)
  • Children's Hospital of Philadelphia (US)
Corresponding author
West, James D.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2022-09-01
Volume
206
Issue
5
Pages
596-607
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4283262510
Cited by
24
References
71
Citations by year
2026: 3 · 2025: 6 · 2024: 6 · 2023: 6 · 2022: 3
FWCI
3.38
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01HL151016, R01HL135011, R01HL095797, P01HL108800, P01HL092870, R01HL145372, R01HL119503, K24HL143281, T32HL094296, K08HL130595)
  • Doris Duke Charitable Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
idiopathic pulmonary fibrosis, thromboxane receptor, fibroblast activation, F2-isoprostanes, oxidative stress, myofibroblast activation, TGF-beta signaling, bleomycin-induced lung fibrosis, Hermansky-Pudlak syndrome, radiation-induced fibrosis, fibrotic remodeling
MeSH terms
Animals, Bleomycin, Fibroblasts, Humans, Lung, Mice, Inbred C57BL, Prostaglandins, Thromboxanes, Transforming Growth Factor beta, Receptors, Thromboxane, F2-Isoprostanes, Mice, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.202106-1503oc
The paper
Suzuki, T., Kropski, J. A., Chen, J., Carrier, E. J., Chen, X., Sherrill, T. P., Winters, N. I., Camarata, J. E., Polosukhin, V. V., Han, W., Rathinasabapathy, A., Gutor, S., Gulleman, P., Sabusap, C., Banovich, N. E., Tanjore, H., Freeman, M. L., Tada, Y., Young, L. R., . . . West, J. D. (2022). Thromboxane–Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202106-1503oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.